MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 11.02.2026
Johnson & Johnson Langfristiger Schuldenstrom 2011-2026 | JNJ
Langfristiger Schuldenstrom Jährlich Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 B | 1.75 B | 1.47 B | 2.13 B | - | - | - | - | 1.5 B | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2.13 B | 1.47 B | 1.77 B |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
117 M | $ 7.68 | - | $ 6.83 B |  Spain |
 |
Altimmune
ALT
|
256 K | $ 3.47 | 3.74 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
135 M | - | - | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
7.93 M | - | - | $ 915 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Heron Therapeutics
HRTX
|
3.04 M | - | - | $ 130 M | USA |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 218.0 | -1.75 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Incyte Corporation
INCY
|
5.7 M | $ 90.75 | -0.03 % | $ 17.7 B | USA |
 |
Inovio Pharmaceuticals
INO
|
2.41 M | $ 1.57 | -0.63 % | $ 34.8 M | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
780 K | $ 12.91 | 1.33 % | $ 778 M | USA |
 |
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
1.37 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | USA |
 |
KalVista Pharmaceuticals
KALV
|
1.98 M | $ 16.73 | -1.59 % | $ 831 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
8.31 M | $ 21.04 | 4.31 % | $ 3.46 B | USA |
 |
Kamada Ltd.
KMDA
|
2.12 M | $ 8.27 | 0.24 % | $ 260 M | Israel |
 |
Karyopharm Therapeutics
KPTI
|
438 K | $ 6.93 | -9.17 % | $ 845 K | USA |
 |
Keros Therapeutics
KROS
|
2.41 M | $ 11.17 | 1.92 % | $ 416 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
425 K | $ 4.3 | 1.37 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |